The genetic basis of graves' Disease

Current Genomics

Volumn 12, Issue 8, 2011, Pages 542-563

  Płoski, Rafał ^a   Szymański, Konrad ^a   Bednarczuk, Tomasz ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Association; Autoimmunity; Graves' disease; HLA; Non HLA genes; Thyroid

Indexed keywords

ALPHA INTERFERON; ANTITHYROID AGENT; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; THYROGLOBULIN; THYROTROPIN RECEPTOR;

ADDISON DISEASE; ARTICLE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DNA SEQUENCE; ENDOCRINE OPHTHALMOPATHY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GRAVES DISEASE; HAPLOTYPE; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROCHIMERISM; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PATHOGENESIS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; X CHROMOSOME INACTIVATION;

EID: 82155168627     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920211798120772     Document Type: Article

References (293)

1. Hall, R.; Stanbury, J.B. Familial studies of autoimmune thyroiditis. Clin. Exp. Immunol., 1967, 2, Suppl-25.
2. Villanueva, R.; Inzerillo, A.M.; Tomer, Y.; Barbesino, G.; Meltzer, M.; Concepcion, E.S.; Greenberg, D.A.; MacLaren, N.; Sun, Z.S.; Zhang, D.M.; Tucci, S.; Davies, T.F. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid, 2000, 10, 791-798.
3. Brix, T.H.; Christensen, K.; Holm, N.V.; Harvald, B.; Hegedus, L. A population-based study of Graves' disease in Danish twins. Clin. Endocrinol.(Oxf), 1998, 48, 397-400.
4. Brix, T.H.; Kyvik, K.O.; Christensen, K.; Hegedus, L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab., 2001, 86, 930-934.
5. Ringold, D.A.; Nicoloff, J.T.; Kesler, M.; Davis, H.; Hamilton, A.; Mack, T. Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid, 2002, 12, 647-653.
6. Stenszky, V.; Kozma, L.; Balazs, C.; Rochlitz, S.; Bear, J.C.; Farid, N.R. The genetics of Graves' disease: HLA and disease susceptibility. J. Clin. Endocrinol. Metab., 1985, 61, 735-740.
7. Farid, N.R. Understanding the genetics of autoimmune thyroid disease--still an illusive goal! J. Clin. Endocrinol. Metab., 1992, 74, 495A-495B.
8. Lander, E.; Kruglyak, L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Genet., 1995, 11, 241-247.
9. Hodge, S.E. What association analysis can and cannot tell us about the genetics of complex disease. Am. J. Med. Genet., 1994, 54, 318-323.
10. Hirschhorn, J.N.; Daly, M.J. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet., 2005, 6, 95-108.
11. The International HapMap Project. Nature, 2003, 426, 789-796.
12. Pearson, T.A.; Manolio, T.A. How to interpret a genome-wide association study. JAMA, 2008, 299, 1335-1344.
13. Surolia, I.; Pirnie, S.P.; Chellappa, V.; Taylor, K.N.; Cariappa, A.; Moya, J.; Liu, H.; Bell, D.W.; Driscoll, D.R.; Diederichs, S.; Haider, K.; Netravali, I.; Le, S.; Elia, R.; Dow, E.; Lee, A.; Freudenberg, J.; De Jager, P.L.; Chretien, Y.; Varki, A.; MacDonald, M.E.; Gillis, T.; Behrens, T.W.; Bloch, D.; Collier, D.; Korzenik, J.; Podolsky, D.K.; Hafler, D.; Murali, M.; Sands, B.; Stone, J.H.; Gregersen, P.K.; Pillai, S. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature, 2010, 466, 243-247.
14. Szymanski, K.; Skorka, A.; Szypowska, A.; Bednarczuk, T.; Ploski, R. Functionally defective germline variant of sialic acid acetylesterase (Met89Val) is not associated with type 1 diabetes mellitus and Graves' disease in a Polish population. Tissue Antigens, 2011.
15. Durbin, R.M.; Abecasis, G.R.; Altshuler, D.L.; Auton, A.; Brooks, L.D.; Durbin, R.M.; Gibbs, R.A.; Hurles, M.E.; McVean, G.A. A map of human genome variation from population-scale sequencing. Nature, 2010, 467, 1061-1073.
16. Simmonds, M.J.; Gough, S.C. The search for the genetic contribution to autoimmune thyroid disease: the never ending story? Brief Funct. Genomics, 2011, 10, 77-90.
17. Kisielow, P.; von Boehmer, H. Development and selection of T cells: facts and puzzles. Adv. Immunol., 1995, 58, 87-209.
18. Rhodes, D.A.; Trowsdale, J. Genetics and molecular genetics of the MHC. Rev. Immunogenet., 1999, 1, 21-31.
19. Monaco, J.J. Pathways for the processing and presentation of antigens to T cells. J. Leukoc. Biol., 1995, 57, 543-547.
20. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature, 1999, 401, 921-923.
21. Gough, S.C.; Simmonds, M.J. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. Curr. Genomics, 2007, 8, 453-465.
22. Simmonds, M.J.; Gough, S.C. Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin. Exp. Immunol., 2004, 136, 1-10.
23. Chen, Q.Y.; Huang, W.; She, J.X.; Baxter, F.; Volpe, R.; Maclaren, N.K. HLA-DRB108, DRB103/DRB30101, and DRB30202 Are Susceptibility Genes for Graves' Disease in North American Caucasians, Whereas DRB107 Is Protective. J. Clin. Endocrinol. Metab., 1999, 84, 3182-3186.
24. Simmonds, M.J.; Howson, J.M.M.; Heward, J.M.; Cordell, H.J.; Foxall, H.; Carr-Smith, J.; Gibson, S.M.; Walker, N.; Tomer, Y.; Franklyn, J.A.; Todd, J.A.; Gough, S.C.L. Regression mapping of association between the human leukocyte antigen region and graves disease. Am. J. Hum. Genet., 2005, 76, 157-163.
25. Kula, D.; Bednarczuk, T.; Jurecka-Lubieniecka, B.; Polanska, J.; Hasse-Lazar, K.; Jarzab, M.; Steinhof-Radwanska, K.; Hejduk, B.; Zebracka, J.; Kurylowicz, A.; Bar-Andziak, E.; Stechly, T.; Pawlaczek, A.; Gubala, E.; Krawczyk, A.; Szpak-Ulczok, S.; Nauman, J.; Jarzab, B. Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1 07. Thyroid, 2006, 16, 447-453.
26. Yanagawa, T.; Mangklabruks, A.; Chang, Y.B.; Okamoto, Y.; Fisfalen, M.E.; Curran, P.G.; DeGroot, L.J. Human histocompatibility leukocyte antigen-DQA1 0501 allele associated with genetic susceptibility to Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab., 1993, 76, 1569-1574.
27. Barlow, A.B.; Wheatcroft, N.; Watson, P.; Weetman, A.P. Association of HLA-DQA1 0501 with Graves' disease in English Caucasian men and women. Clin. Endocrinol. (Oxf), 1996, 44, 73-77.
28. Gregersen, P.K.; Silver, J.; Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum., 1987, 30, 1205-1213.
29. Ban, Y.; Davies, T.F.; Greenberg, D.A.; Concepcion, E.S.; Osman, R.; Oashi, T.; Tomer, Y. Arginine at position 74 of the HLA-DR [beta]1 chain is associated with Graves' disease. Genes Immun., 2004, 5, 203-208.
30. Menconi, F.; Monti, M.C.; Greenberg, D.A.; Oashi, T.; Osman, R.; Davies, T.F.; Ban, Y.; Jacobson, E.M.; Concepcion, E.S.; Li, C.W.; Tomer, Y. Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice. PNAS, 2008, 105, 14034-14039.
31. Menconi, F.; Osman, R.; Monti, M.C.; Greenberg, D.A.; Concepcion, E.S.; Tomer, Y. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. PNAS, 2010, 107, 16899-16903.
32. Simmonds, M.J.; Howson, J.M.M.; Heward, J.M.; Carr-Smith, J.; Franklyn, J.A.; Todd, J.A.; Gough, S.C.L. A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum. Mol. Genet., 2007, 16, 2149-2153.
33. Weetman, A.P.; Zhang, L.; Webb, S.; Shine, B. Analysis of HLADQB and HLA-DPB alleles in Graves' disease by oligonucleotide probing of enzymatically amplified DNA. Clin. Endocrinol. (Oxf), 1990, 33, 65-71.
34. Ratanachaiyavong, S., McGregor, A.M. HLA-DPB1 polymorphisms on the MHC-extended haplotypes of families of patients with Graves' disease: two distinct HLA-DR17 haplotypes. Eur. J. Clin. Invest., 1994, 24, 309-315.
35. Hunt, P.J.; Marshall, S.E.; Weetman, A.P.; Bunce, M.; Bell, J.I.; Wass, J.A.H.; Welsh, K.I. Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin. Endocrinol., 2001, 55, 491-499.
36. Chen, P.L.; Fann, C.S.-J.; Chu, C.C.; Chang, C.C.; Chang, S.W.; Hsieh, H.Y.; Lin, M.; Yang, W.S.; Chang, T.C. Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles. PLoS ONE, 2011, 6, e16635.
37. Sridama, V.; Hara, Y.; Fauchet, R.; DeGroot, L.J. HLA immunogenetic heterogeneity in black american patients with Graves' Disease. Arch. Intern. Med., 1987, 147, 229-231.
38. Omar, M.A.; Hammond, M.G.; Desai, R.K.; Motala, A.A.; Aboo, N.; Seedat, M.A. HLA class I and II antigens in South African blacks with Graves' disease. Clin. Immunol. Immunopathol., 1990, 54, 98-102.
39. Ofosu, M.H.; Dunston, G.; Henry, L.; Ware, D.; Cheatham, W.; Brembridge, A.; Brown, C.; Alarif, L. HLA-DQ3 is associated with Graves' disease in African-Americans. Immunol. Invest., 1996, 25, 103-110.
40. Yanagawa, T.; DeGroot, L.J. HLA class II associations in African- American female patients with Graves' disease. Thyroid, 1996, 6, 37-39.
41. Chen, Q.Y.; Nadell, D.; Zhang, X.Y.; Kukreja, A.; Huang, Y.J.; Wise, J.; Svec, F.; Richards, R.; Friday, K.E.; Vargas, A.; Gomez, R.; Chalew, S.; Lan, M.S.; Tomer, Y.; Maclaren, N.K. The Human Leukocyte Antigen HLA DRB3 0202/DQA1 0501 Haplotype is associated with Graves' Disease in African Americans. J. Clin. Endocrinol. Metab., 2000, 85, 1545-1549.
42. Smikle, M.F.; Pascoe, R.W.; Barton, E.; Morgan, O.; Christian, N.; Dowe, G.; Roye-Green, K.; Bailey, V.; James, O. HLADRB3 0101 is associated with Graves' disease in Jamaicans. Clin. Endocrinol., 2001, 55, 805-808.
43. Bottini, N.; Musumeci, L.; Alonso, A.; Rahmouni, S.; Nika, K.; Rostamkhani, M.; MacMurray, J.; Meloni, G.F.; Lucarelli, P.; Pellecchia, M.; Eisenbarth, G.S.; Comings, D.; Mustelin, T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet., 2004, 36, 337-338.
44. Smyth, D.; Cooper, J.D.; Collins, J.E.; Heward, J.M.; Franklyn, J.A.; Howson, J.M.; Vella, A.; Nutland, S.; Rance, H.E.; Maier, L.; Barratt, B.J.; Guja, C.; Ionescu-Tirgoviste, C.; Savage, D.A.; Dunger, D.B.; Widmer, B.; Strachan, D.P.; Ring, S.M.; Walker, N.; Clayton, D.G.; Twells, R.C.; Gough, S.C.; Todd, J.A. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes, 2004, 53, 3020-3023.
45. Lee, Y.H.; Rho, Y.H.; Choi, S.J.; Ji, J.D.; Song, G.G.; Nath, S.K.; Harley, J.B. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology, 2007, 46, 49-56.
46. Cohen, S.; Dadi, H.; Shaoul, E.; Sharfe, N.; Roifman, C.M. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood, 1999, 93, 2013-2024.
47. Cloutier, J.F.; Veillette, A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J. Exp. Med., 1999, 189, 111-121.
48. Begovich, A.B.; Carlton, V.E.H.; Honigberg, L.A.; Schrodi, S.J.; Chokkalingam, A.P.; Alexander, H.C.; Ardlie, K.G.; Huang, Q.; Smith, A.M.; Spoerke, J.M.; Conn, M.T.; Chang, M.; Chang, S.Y.; Saiki, R.K.; Catanese, J.J.; Leong, D.U.; Garcia, V.E.; McAllister, L.B.; Jeffery, D.A.; Lee, A.T.; Batliwalla, F.; Remmers, E.; Criswell, L.A.; Seldin, M.F.; Kastner, D.L.; Amos, C.I.; Sninsky, J.J.; Gregersen, P.K. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet., 2004, 75, 330-337.
49. Vang, T.; Congia, M.; Macis, M.D.; Musumeci, L.; Orru, V.; Zavattari, P.; Nika, K.; Tautz, L.; Tasken, K.; Cucca, F.; Mustelin, T.; Bottini, N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet., 2005, 37, 1317-1319.
50. Rieck, M.; Arechiga, A.; Onengut-Gumuscu, S.; Greenbaum, C.; Concannon, P.; Buckner, J.H. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol., 2007, 179, 4704-4710.
51. Hasegawa, K.; Martin, F.; Huang, G.; Tumas, D.; Diehl, L.; Chan, A.C. Pest domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory t cells. Science, 2004, 303, 685-689.
52. Lefvert, A.K.; Zhao, Y.; Ramanujam, R.; Yu, S.; Pirskanen, R.; Hammarstrom, L. PTPN22 R620W promotes production of anti- AChR autoantibodies and IL-2 in myasthenia gravis. J. Neuroimmunol., 2008, 197, 110-113.
53. Gregersen, P.K.; Lee, H.S.; Batliwalla, F.; Begovich, A.B. PTPN22: setting thresholds for autoimmunity. Semin. Immunol., 2006, 18, 214-223.
54. Arechiga, A.F.; Habib, T.; He, Y.; Zhang, X.; Zhang, Z.Y.; Funk, A.; Buckner, J.H. Cutting Edge: The PTPN22 Allelic Variant Associated with Autoimmunity Impairs B Cell Signaling. J. Immunol., 2009, 182, 3343-3347.
55. Siggs, O.M.; Miosge, L.A.; Yates, A.L.; Kucharska, E.M.; Sheahan, D.; Brdicka, T.; Weiss, A.; Liston, A.; Goodnow, C.C. Opposing Functions of the T Cell Receptor Kinase ZAP-70 in Immunity and Tolerance Differentially Titrate in Response to Nucleotide Substitutions. Immunity, 2007, 27, 912-926.
56. Stanford, S.M.; Mustelin, T.M.; Bottini, N. Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin. Immunopathol., 2010, 32, 127-136.
57. Skorka, A.; Bednarczuk, T.; Bar-Andziak, E.; Nauman, J.; Ploski, R. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dosedependent correlation with age of onset. Clin. Endocrinol. (Oxf), 2005, 62, 679-682.
58. Velaga, M.R.; Wilson, V.; Jennings, C.E.; Owen, C.J.; Herington, S.; Donaldson, P.T.; Ball, S.G.; James, R.A.; Quinton, R.; Perros, P.; Pearce, S.H.S. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of graves' disease. J. Clin. Endocrinol. Metab., 2004, 89, 5862-5865.
59. Zhebrun, D.; Kudryashova, Y.; Babenko, A.; Maslyansky, A.; Kunitskaya, N.; Popcova, D.; Klushina, A.; Grineva, E.; Kostareva, A.; Shlyakhto, E. Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population. Aging (Albany.NY), 2011.
60. Zeitlin, A.A.; Heward, J.M.; Brand, O.J.; Newby, P.R.; Franklyn, J.A.; Gough, S.C.L.; Simmonds, M.J. Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with GravesGÇÖ disease. Clin. Endocrinol., 2006, 65, 380-384.
61. Zhang, J.; Feuk, L.; Duggan, G.E.; Khaja, R.; Scherer, S.W. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet. Genome Res., 2006, 115, 205-214.
62. Huber, A.K.; Concepcion, E.S.; Gandhi, A.; Menconi, F.; Smith, E.P.; Keddache, M.; Tomer, Y. Analysis of immune regulatory genes' copy number variants in Graves' disease. Thyroid, 2011, 21, 69-74.
63. Orru, V.; Tsai, S.J.; Rueda, B.; Fiorillo, E.; Stanford, S.M.; Dasgupta, J.; Hartiala, J.; Zhao, L.; Ortego-Centeno, N.; D'Alfonso, S.; The Italian Collaborative Group; Arnett, F.C.; Wu, H.; Gonzalez-Gay, M.A.; Tsao, B.P.; Pons-Estel, B.; Alarcon- Riquelme, M.E.; He, Y.; Zhang, Z.Y.; Allayee, H.; Chen, X.S.; Martin, J.; Bottini, N. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum. Mol. Genet., 2009, 18, 569-579.
64. Heward, J.M.; Brand, O.J.; Barrett, J.C.; Carr-Smith, J.D.; Franklyn, J.A.; Gough, S.C. Association of PTPN22 haplotypes with Graves' disease. J. Clin. Endocrinol. Metab., 2007, 92, 685-690.
65. Carlton, V.E.H.; Hu, X.; Chokkalingam, A.P.; Schrodi, S.J.; Brandon, R.; Alexander, H.C.; Chang, M.; Catanese, J.J.; Leong, D.U.; Ardlie, K.G.; Kastner, D.L.; Seldin, M.F.; Criswell, L.A.; Gregersen, P.K.; Beasley, E.; Thomson, G.; Amos, C.I.; Begovich, A.B. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet., 2005, 77, 567-581.
66. Zhang, Z.H.; Chen, F.; Zhang, X.L.; Jin, Y.; Bai, J.; Fu, S.B. PTPN22 allele polymorphisms in 15 Chinese populations. Int. J. Immunogenet., 2008, 35, 433-437.
67. Mori, M.; Yamada, R.; Kobayashi, K.; Kawaida, R.; Yamamoto, K. Ethnic differences in allele frequency of autoimmune-diseaseassociated SNPs. J. Hum. Genet., 2005, 50, 264-266.
68. Ban, Y.; Tozaki, T.; Taniyama, M.; Tomita, M.; Ban, Y. The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase-22 gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese. Thyroid, 2005, 15, 1115-1118.
69. Ban, Y.; Tozaki, T.; Taniyama, M.; Nakano, Y.; Ban, Y.; Ban, Y.; Hirano, T. Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population. Thyroid, 2010,
70. Tomer, Y.; Concepcion, E.; Greenberg, D.A. A C/T Single- Nucleotide polymorphism in the region of the CD40 gene is associated with Graves' Disease. Thyroid, 2002, 12, 1129-1135.
71. Jacobson, E.M.; Concepcion, E.; Oashi, T.; Tomer, Y. A graves' disease-associated kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: A case for translational pathophysiology. Endocrinology, 2005, 146, 2684-2691.
72. Heward, J.M.; Simmonds, M.J.; Carr-Smith, J.; Foxall, H.; Franklyn, J.A.; Gough, S.C. A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin. Endocrinol. (Oxf), 2004, 61, 269-272.
73. Houston, F.A.; Wilson, V.; Jennings, C.E.; Owen, C.J.; Donaldson, P.; Perros, P.; Pearce, S.H.S. Role of the CD40 locus in graves' disease. Thyroid, 2004, 14, 506-509.
74. Kurylowicz, A.; Kula, D.; Ploski, R.; Skorka, A.; Jurecka- Lubieniecka, B.; Zebracka, J.; Steinhof-Radwanska, K.; Hasse- Lazar, K.; Hiromatsu, Y.; Jarzab, B.; Bednarczuk, T. Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid, 2005, 15, 1119-1124.
75. Mukai, T.; Hiromatsu, Y.; Fukutani, T.; Ichimura, M.; Kaku, H.; Miyake, I.; Yamada, K. A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of graves' disease in Japanese. Endocr. J., 2005, 52, 471-77.
76. Ban, Y.; Tozaki, T.; Taniyama, M.; Tomita, M.; Ban, Y. Association of a C/T single-nucleotide polymorphism in the 5' untranslated region of the CD40 gene with graves' disease in Japanese. Thyroid, 2006, 16, 443-446.
77. Caux, C.; Massacrier, C.; Vanbervliet, B.; Dubois, B.; Van Kooten, C.; Durand, I.; Banchereau, J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med., 1994, 180, 1263-1272.
78. Metcalfe, R.A.; McIntosh, R.S.; Marelli-Berg, F.; Lombardi, G.; Lechler, R.; Weetman, A.P. Detection of CD40 on human thyroid follicular cells: analysis of expression and function. J. Clin. Endocrinol. Metab., 1998, 83, 1268-1274.
79. Smith, T.J.; Sempowski, G.D.; Berenson, C.S.; Cao, H.J.; Wang, H.S.; Phipps, R.P. Human thyroid fibroblasts exhibit a distinctive phenotype in culture: characteristic ganglioside profile and functional CD40 expression. Endocrinology, 1997, 138, 5576-5588.
80. Clark, L.B.; Foy, T.M.; Noelle, R.J. CD40 and its ligand. Adv. Immunol., 1996, 63, 43-78.
81. Chatzigeorgiou, A.; Lyberi, M.; Chatzilymperis, G.; Nezos, A.; Kamper, E. CD40/CD40L signaling and its implication in health and disease. Biofactors, 2009, 35, 474-483.
82. Hollenbaugh, D.; Grosmaire, L.S.; Kullas, C.D.; Chalupny, N.J.; Braesch-Andersen, S.; Noelle, R.J.; Stamenkovic, I.; Ledbetter, J.A.; Aruffo, A. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J., 1992, 11, 4313-4321.
83. Ye, F.; Shi, B.; Wu, X.; Hou, P.; Gao, L.; Ma, X.; Xu, L.; Wu, L. Experience with lentivirus-mediated CD40 gene silencing in a mouse model of Graves' disease. J. Endocrinol., 2011, 208, 285-291.
84. Puck, J.M.; Willard, H.F. X inactivation in females with X-linked disease. N. Engl. J. Med., 1998, 338, 325-328.
85. Walunas, T.L.; Bakker, C.Y.; Bluestone, J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med., 1996, 183, 2541-2550.
86. Gough, S.C.; Walker, L.S.; Sansom, D.M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev., 2005, 204, 102-115.
87. Schneider, H.; Downey, J.; Smith, A.; Zinselmeyer, B.H.; Rush, C.; Brewer, J.M.; Wei, B.; Hogg, N.; Garside, P.; Rudd, C.E. Reversal of the TCR stop signal by CTLA-4. Science, 2006, 313, 1972-1975.
88. Downey, J.; Smith, A.; Schneider, H.; Hogg, N.; Rudd, C.E. TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice. Immunol. Lett., 2008, 115, 70-72.
89. Schneider, H.; Smith, X.; Liu, H.; Bismuth, G.; Rudd, C.E. CTLA- 4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur. J. Immunol., 2008, 38, 40-47.
90. Buemann, B.; Astrup, A. How does the body deal with energy from alcohol? Nutrition, 2001, 17, 638-641.
91. Oaks, M.K.; Hallett, K.M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol., 2000, 164, 5015-5018.
92. Liu, M.F.; Wang, C.R.; Chen, P.C.; Fung, L.L. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand. J. Immunol., 2003, 57, 568-572.
93. Qureshi, O.S.; Zheng, Y.; Nakamura, K.; Attridge, K.; Manzotti, C.; Schmidt, E.M.; Baker, J.; Jeffery, L.E.; Kaur, S.; Briggs, Z.; Hou, T.Z.; Futter, C.E.; Anderson, G.; Walker, L.S.; Sansom, D.M. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science, 2011, 332, 600-603.
94. Yanagawa, T.; Hidaka, Y.; Guimaraes, V.; Soliman, M.; DeGroot, L.J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab., 1995, 80, 41-45.
95. Donner, H.; Rau, H.; Walfish, P.G.; Braun, J.; Siegmund, T.; Finke, R.; Herwig, J.; Usadel, K.H.; Badenhoop, K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab., 1997, 82, 143-146.
96. Takara, M.; Kouki, T.; DeGroot, L.J. CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. Thyroid, 2003, 13, 1083-1089.
97. Chistiakov, D.A.; Savost'anov, K.V.; Turakulov, R.I.; Efremov, I.A.; Demurov, L.M. Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin. Immunol., 2006, 118, 233-242.
98. Heward, J.M.; Allahabadia, A.; Armitage, M.; Hattersley, A.; Dodson, P.M.; Macleod, K.; Carr-Smith, J.; Daykin, J.; Daly, A.; Sheppard, M.C.; Holder, R.L.; Barnett, A.H.; Franklyn, J.A.; Gough, S.C. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J. Clin. Endocrinol. Metab., 1999, 84, 2398-2401.
99. Chistyakov, D.A.; Savost'anov, K.V.; Turakulov, R.I.; Petunina, N.A.; Trukhina, L.V.; Kudinova, A.V.; Balabolkin, M.I.; Nosikov, V.V. Complex association analysis of Graves disease using a set of polymorphic markers. Mol. Genet. Metab., 2000, 70, 214-218.
100. Kouki, T.; Gardine, C.A.; Yanagawa, T.; DeGroot, L.J. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J. Endocrinol. Invest., 2002, 25, 208-213.
101. Ban, Y.; Concepcion, E.S.; Villanueva, R.; Greenberg, D.A.; Davies, T.F.; Tomer, Y. Analysis of immune regulatory genes in familial and sporadic Graves' disease. J. Clin. Endocrinol. Metab., 2004, 89, 4562-4568.
102. Furugaki, K.; Shirasawa, S.; Ishikawa, N.; Ito, K.; Ito, K.; Kubota, S.; Kuma, K.; Tamai, H.; Akamizu, T.; Hiratani, H.; Tanaka, M.; Sasazuki, T. Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese. J. Hum. Genet., 2004, 49, 166-168.
103. Vaidya, B.; Imrie, H.; Perros, P.; Young, E.T.; Kelly, W.F.; Carr, D.; Large, D.M.; Toft, A.D.; McCarthy, M.I.; Kendall-Taylor, P.; Pearce, S.H. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum. Mol. Genet., 1999, 8, 1195-1199.
104. Anjos, S.; Nguyen, A.; Ounissi-Benkalha, H.; Tessier, M.C.; Polychronakos, C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem., 2002, 277, 46478-46486.
105. Xu, Y.; Graves, P.N.; Tomer, Y.; Davies, T.F. CTLA-4 and autoimmune thyroid disease: lack of influence of the A49G signal peptide polymorphism on functional recombinant human CTLA-4. Cell Immunol., 2002, 215, 133-140.
106. Daroszewski, J.; Pawlak, E.; Karabon, L.; Frydecka, I.; Jonkisz, A.; Slowik, M.; Bolanowski, M. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur. J. Endocrinol., 2009, 161, 787-793.
107. Petrone, A.; Giorgi, G.; Galgani, A.; Alemanno, I.; Corsello, S.M.; Signore, A.; Di Mario, U.; Nistico, L.; Cascino, I.; Buzzetti, R. CT60 single nucleotide polymorphisms of the cytotoxic Tlymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid, 2005, 15, 232-238.
108. Ban, Y.; Tozaki, T.; Taniyama, M.; Tomita, M.; Ban, Y. Association of a CTLA-4 3' untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity, 2005, 38, 151-153.
109. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Snook, H.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.; Smith, A.N.; Di Genova, G.; Herr, M.H.; Dahlman, I.; Payne, F.; Smyth, D.; Lowe, C.; Twells, R.C.; Howlett, S.; Healy, B.; Nutland, S.; Rance, H.E.; Everett, V.; Smink, L.J.; Lam, A.C.; Cordell, H.J.; Walker, N.M.; Bordin, C.; Hulme, J.; Motzo, C.; Cucca, F.; Hess, J.F.; Metzker, M.L.; Rogers, J.; Gregory, S.; Allahabadia, A.; Nithiyananthan, R.; Tuomilehto-Wolf, E.; Tuomilehto, J.; Bingley, P.; Gillespie, K.M.; Undlien, D.E.; Ronningen, K.S.; Guja, C.; Ionescu-Tirgoviste, C.; Savage, D.A.; Maxwell, A.P.; Carson, D.J.; Patterson, C.C.; Franklyn, J.A.; Clayton, D.G.; Peterson, L.B.; Wicker, L.S.; Todd, J.A.; Gough, S.C. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 2003, 423, 506-511.
110. Magistrelli, G.; Jeannin, P.; Herbault, N.; Benoit, D.C.; Gauchat, J.F.; Bonnefoy, J.Y.; Delneste, Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol., 1999, 29, 3596-3602.
111. Mayans, S.; Lackovic, K.; Nyholm, C.; Lindgren, P.; Ruikka, K.; Eliasson, M.; Cilio, C.M.; Holmberg, D. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC. Med. Genet., 2007, 8, 3.
112. Takahashi, M.; Kimura, A. HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves' disease. J. Hum. Genet., 2010, 55, 323-326.
113. Kavvoura, F.K.; Akamizu, T.; Awata, T.; Ban, Y.; Chistiakov, D.A.; Frydecka, I.; Ghaderi, A.; Gough, S.C.; Hiromatsu, Y.; Ploski, R.; Wang, P.W.; Ban, Y.; Bednarczuk, T.; Chistiakova, E.I.; Chojm, M.; Heward, J.M.; Hiratani, H.; Juo, S.H.; Karabon, L.; Katayama, S.; Kurihara, S.; Liu, R.T.; Miyake, I.; Omrani, G.H.; Pawlak, E.; Taniyama, M.; Tozaki, T.; Ioannidis, J.P. Cytotoxic Tlymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J. Clin. Endocrinol. Metab., 2007, 92, 3162-3170.
114. Weetman, A.P. Graves' disease by any other name? Thyroid, 2000, 10, 1071-1072.
115. Akamizu, T.; Ikuyama, S.; Saji, M.; Kosugi, S.; Kozak, C.; McBride, O.W.; Kohn, L.D. Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. Proc. Natl. Acad. Sci. USA, 1990, 87, 5677-5681.
116. Rousseau-Merck, M.F.; Misrahi, M.; Loosfelt, H.; Atger, M.; Milgrom, E.; Berger, R. Assignment of the human thyroid stimulating hormone receptor (TSHR) gene to chromosome 14q31. Genomics, 1990, 8, 233-236.
117. Kakinuma, A.; Nagayama, Y. Multiple messenger ribonucleic acid transcripts and revised gene organization of the human TSH receptor. Endocr. J., 2002, 49, 175-180.
118. Gustavsson, B.; Eklof, C.; Westermark, K.; Westermark, B.; Heldin, N.E. Functional analysis of a variant of the thyrotropin receptor gene in a family with Graves' disease. Mol. Cell Endocrinol., 1995, 111, 167-173.
119. Chistiakov, D.A.; Savost'anov, K.V.; Turakulov, R.I. Screening of SNPs at 18 positional candidate genes, located within the GD-1 locus on chromosome 14q23-q32, for susceptibility to Graves' disease: a TDT study. Mol. Genet. Metab., 2004, 83, 264-270.
120. Chistiakov, D.A.; Savost'anov, K.V.; Turakulov, R.I.; Petunina, N.; Balabolkin, M.I.; Nosikov, V.V. Further studies of genetic susceptibility to Graves' disease in a Russian population. Med. Sci. Monit., 2002, 8, CR180-CR184.
121. Ban, Y.; Greenberg, D.A.; Concepcion, E.S.; Tomer, Y. A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves' disease. Thyroid, 2002, 12, 1079-1083.
122. Simanainen, J.; Kinch, A.; Westermark, K.; Winsa, B.; Bengtsson, M.; Schuppert, F.; Westermark, B.; Heldin, N.E. Analysis of mutations in exon 1 of the human thyrotropin receptor gene: High frequency of the D36H and P52T polymorphic variants. Thyroid, 1999, 9, 7-11.
123. Kaczur, V.; Takacs, M.; Szalai, C.; Falus, A.; Nagy, Z.; Berencsi, G.; Balazs, C. Analysis of the genetic variability of the 1st (CCC/ACC, P52T) and the 10th exons (bp 1012-1704) of the TSH receptor gene in Graves' disease. Eur. J. Immunogenet., 2000, 27, 17-23.
124. de Roux, N.; Shields, D.C.; Misrahi, M.; Ratanachaiyavong, S.; McGregor, A.M.; Milgrom, E. Analysis of the thyrotropin receptor as a candidate gene in familial Graves' disease. J. Clin. Endocrinol. Metab., 1996, 81, 3483-3486.
125. Tomer, Y.; Ban, Y.; Concepcion, E.; Barbesino, G.; Villanueva, R.; Greenberg, D.A.; Davies, T.F. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am. J. Hum. Genet., 2003, 73, 736-747.
126. Akamizu, T.; Sale, M.M.; Rich, S.S.; Hiratani, H.; Noh, J.Y.; Kanamoto, N.; Saijo, M.; Miyamoto, Y.; Saito, Y.; Nakao, K.; Bowden, D.W. Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA- 4 in Japanese patients. Thyroid, 2000, 10, 851-858.
127. Hiratani, H.; Bowden, D.W.; Ikegami, S.; Shirasawa, S.; Shimizu, A.; Iwatani, Y.; Akamizu, T. Multiple SNPs in intron 7 of thyrotropin receptor are associated with graves' disease. J. Clin. Endocrinol. Metab., 2005, 90, 2898-2903.
128. Dechairo, B.M.; Zabaneh, D.; Collins, J.; Brand, O.; Dawson, G.J.; Green, A.P.; Mackay, I.; Franklyn, J.A.; Connell, J.M.; Wass, J.A.; Wiersinga, W.M.; Hegedus, L.; Brix, T.; Robinson, B.G.; Hunt, P.J.; Weetman, A.P.; Carey, A.H.; Gough, S.C. Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur. J. Hum. Genet., 2005, 13, 1223-1230.
129. Brand, O.J.; Barrett, J.C.; Simmonds, M.J.; Newby, P.R.; McCabe, C.J.; Bruce, C.K.; Kysela, B.; Carr-Smith, J.D.; Brix, T.; Hunt, P.J.; Wiersinga, W.M.; Hegedus, L.; Connell, J.; Wass, J.A.H.; Franklyn, J.A.; Weetman, A.P.; Heward, J.M.; Gough, S.C.L. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum. Mol. Genet., 2009, 18, 1704-1713.
130. Chen, C.R.; Pichurin, P.; Nagayama, Y.; Latrofa, F.; Rapoport, B.; McLachlan, S.M. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J. Clin. Invest., 2003, 111, 1897-1904.
131. Ploski, R.; Brand, O.J.; Jurecka-Lubieniecka, B.; Franaszczyk, M.; Kula, D.; Krajewski, P.; Karamat, M.A.; Simmonds, M.J.; Franklyn, J.A.; Gough, S.C.; Jarzab, B.; Bednarczuk, T. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS ONE, 2010, 5, e15512.
132. Ho, S.C.; Goh, S.S.; Khoo, D.H. Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid, 2003, 13, 523-528.
133. Wellcome Trust Case Control Consortium, Australo-Anglo- American Spondylitis Consortium (TASC) Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet., 2007, 39, 1329-1337.
134. Sakai, K.; Shirasawa, S.; Ishikawa, N.; Ito, K.; Tamai, H.; Kuma, K.; Akamizu, T.; Tanimura, M.; Furugaki, K.; Yamamoto, K.; Sasazuki, T. Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23- q24 by multipoint affected sib-pair linkage analysis in Japanese. Hum. Mol. Genet., 2001, 10, 1379-1386.
135. Ban, Y.; Greenberg, D.A.; Davies, T.F.; Jacobson, E.; Concepcion, E.; Tomer, Y. 'Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. J. Clin. Endocrinol. Metab., 2008, 93, 3589-3596.
136. Collins, J.E.; Heward, J.M.; Carr-Smith, J.; Daykin, J.; Franklyn, J.A.; Gough, S.C. Association of a rare thyroglobulin gene microsatellite variant with autoimmune thyroid disease. J. Clin. Endocrinol. Metab., 2003, 88, 5039-5042.
137. Ban, Y.; Greenberg, D.A.; Concepcion, E.; Skrabanek, L.; Villanueva, R.; Tomer, Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 15119-15124.
138. Maierhaba, M.; Zhang, J.A.; Yu, Z.Y.; Wang, Y.; Xiao, W.X.; Quan, Y.; Dong, B.N. Association of the thyroglobulin gene polymorphism with autoimmune thyroid disease in Chinese population. Endocrine, 2008, 33, 294-299.
139. Caputo, M.; Rivolta, C.M.; Mories, T.; Corrales, J.J.; Galindo, P.; Gonzalez-Sarmiento, R.; Targovnik, H.M.; Miralles-Garcia, J.M. Analysis of thyroglobulin gene polymorphisms in patients with autoimmune thyroiditis. Endocrine, 2010, 37, 389-395.
140. Varela, V.; Rizzo, L.; Domene, S.; Bruno, O.D.; Tellechea, M.L.; Rivolta, C.M.; Targovnik, H.M. Association of the TGrI29 microsatellite in thyroglobulin gene with autoimmune thyroiditis in a Argentinian population: a case-control study. Endocrine, 2010, 38, 320-327.
141. Ban, Y.; Tozaki, T.; Taniyama, M.; Tomita, M.; Ban, Y. Association of a thyroglobulin gene polymorphism with Hashimoto's thyroiditis in the Japanese population. Clin. Endocrinol. (Oxf), 2004, 61, 263-268.
142. Hsiao, J.Y.; Hsieh, M.C.; Tien, K.J.; Hsu, S.C.; Shin, S.J.; Lin, S.R. Association between a C/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves' hyperthyroidism after antithyroid withdrawal in Taiwanese. J. Clin. Endocrinol. Metab., 2007, 92, 3197-3201.
143. Hsiao, J.Y.; Hsieh, M.C.; Hsiao, C.T.; Weng, H.H.; Ke, D.S. Association of CD40 and thyroglobulin genes with later-onset Graves' disease in Taiwanese patients. Eur. J. Endocrinol., 2008, 159, 617-621.
144. Hsiao, J.Y.; Hsieh, M.C.; Tien, K.J.; Hsu, S.C.; Lin, S.R.; Ke, D.S. Exon 33 T/T genotype of the thyroglobulin gene is a susceptibility gene for Graves' disease in Taiwanese and exon 12 C/C genotype protects against it. Clin. Exp. Med., 2008, 8, 17-21.
145. Gu, L.Q.; Zhu, W.; Zhao, S.X.; Zhao, L.; Zhang, M.J.; Cui, B.; Song, H.D.; Ning, G.; Zhao, Y.J. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin. Endocrinol. (Oxf), 2010, 72, 248-255.
146. Tanrikulu, S.; Erbil, Y.; Ademoglu, E.; Issever, H.; Barbaros, U.; Kutluturk, F.; Ozarmagan, S.; Tezelman, S. The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal. Endocrine, 2006, 30, 377-381.
147. Collins, J.E.; Heward, J.M.; Howson, J.M.; Foxall, H.; Carr-Smith, J.; Franklyn, J.A.; Gough, S.C. Common allelic variants of exons 10, 12, and 33 of the thyroglobulin gene are not associated with autoimmune thyroid disease in the United Kingdom. J. Clin. Endocrinol. Metab., 2004, 89, 6336-6339.
148. Wan, Q.; Shah, R.; Panos, J.C.; Giraldo, A.A.; David, C.S.; Kong, Y.M. HLA-DR and HLA-DQ polymorphism in human thyroglobulin-induced autoimmune thyroiditis: DR3 and DQ8 transgenic mice are susceptible. Hum. Immunol., 2002, 63, 301-310.
149. Menconi, F.; Huber, A.; Osman, R.; Concepcion, E.; Jacobson, E.M.; Stefan, M.; David, C.S.; Tomer, Y. Tg.2098 is a major human thyroglobulin T-cell epitope. J. Autoimmun., 2010, 35, 45-51.
150. Jacobson, E.M.; Concepcion, E.; Ho, K.; Kopp, P.; Vono, T.J.; Tomer, Y. cDNA immunization of mice with human thyroglobulin generates both humoral and T cell responses: a novel model of thyroid autoimmunity. PLoS ONE, 2011, 6, e19200.
151. Hodge, S.E.; Ban, Y.; Strug, L.J.; Greenberg, D.A.; Davies, T.F.; Concepcion, E.S.; Villanueva, R.; Tomer, Y. Possible interaction between HLA-DRbeta1 and thyroglobulin variants in Graves' disease. Thyroid, 2006, 16, 351-355.
152. Stefan, M.; Jacobson, E.M.; Huber, A.K.; Greenberg, D.A.; Li, C.W.; Skrabanek, L.; Conception, E.; Fadlalla, M.; Ho, K.; Tomer, Y. A novel variant of the thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J. Biol. Chem., 2011.
153. Kochi, Y.; Yamada, R.; Suzuki, A.; Harley, J.B.; Shirasawa, S.; Sawada, T.; Bae, S.C.; Tokuhiro, S.; Chang, X.; Sekine, A.; Takahashi, A.; Tsunoda, T.; Ohnishi, Y.; Kaufman, K.M.; Kang, C.P.; Kang, C.; Otsubo, S.; Yumura, W.; Mimori, A.; Koike, T.; Nakamura, Y.; Sasazuki, T.; Yamamoto, K. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet., 2005, 37, 478-485.
154. Swainson, L.A.; Mold, J.E.; Bajpai, U.D.; McCune, J.M. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory t cells is associated with dysfunction and high levels of programmed cell death-1. J. Immunol., 2010, 184, 3639-3647.
155. Simmonds, M.J.; Heward, J.M.; Carr-Smith, J.; Foxall, H.; Franklyn, J.A.; Gough, S.C.L. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of graves' disease. J. Clin. Endocrinol. Metab., 2006, 91, 1056-1061.
156. Owen, C.J.; Kelly, H.; Eden, J.A.; Merriman, M.E.; Pearce, S.H.S.; Merriman, T.R. Analysis of the Fc Receptor-Like-3 (FCRL3) locus in caucasians with autoimmune disorders suggests a complex pattern of disease association. J. Clin. Endocrinol. Metab., 2007, 92, 1106-1111.
157. Simmonds, M.J.; Brand, O.J.; Barrett, J.C.; Newby, P.R.; Franklyn, J.A.; Gough, S.C. Association of Fc receptor-like 5 (FCRL5) with Graves' disease is secondary to the effect of FCRL3. Clin. Endocrinol. (Oxf), 2010, 73, 654-660.
158. Song, H.D.; Liang, J.; Shi, J.Y.; Zhao, S.X.; Liu, Z.; Zhao, J.J.; Peng, Y.D.; Gao, G.Q.; Tao, J.; Pan, C.M.; Shao, L.; Cheng, F.; Wang, Y.; Yuan, G.Y.; Xu, C.; Han, B.; Huang, W.; Chu, X.; Chen, Y.; Sheng, Y.; Li, R.Y.; Su, Q.; Gao, L.; Jia, W.P.; Jin, L.; Chen, M.D.; Chen, S.J.; Chen, Z.; Chen, J.L. Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves' disease. Hum. Mol. Genet., 2009, 18, 1156-1170.
159. Jin, Y.; Teng, W.; Ben, S.; Xiong, X.; Zhang, J.; Xu, S.; Shugart, Y.Y.; Jin, L.; Chen, J.; Huang, W. Genome-wide scan of Graves' disease: evidence for linkage on chromosome 5q31 in Chinese Han pedigrees. J. Clin. Endocrinol. Metab., 2003, 88, 1798-1803.
160. Simmonds, M.J.; Yesmin, K.; Newby, P.R.; Brand, O.J.; Franklyn, J.A.; Gough, S.C.L. Confirmation of association of chromosome 5q31.33 with United Kingdom caucasian graves' disease. Thyroid, 2010, 20, 413-417.
161. Chistiakov, D.A.; Voronova, N.V.; Turakulov, R.I.; Savost'anov, K.V. The -112G > A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves' disease in subsets of patients with elevated levels of immunoglobulin E. J. Appl. Genet., 2011, 52, 201-207.
162. Yang, Y.; Lingling, S.; Ying, J.; Yushu, L.; Zhongyan, S.; Wei, H.; Weiping, T. Association study between the IL4, IL13, IRF1 and UGRP1 genes in chromosomal 5q31 region and Chinese Graves' disease. J. Hum. Genet., 2005, 50, 574-582.
163. Niimi, T.; Munakata, M.; Keck-Waggoner, C.L.; Popescu, N.C.; Levitt, R.C.; Hisada, M.; Kimura, S. A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma. Am. J. Hum. Genet., 2002, 70, 718-725.
164. Inoue, K.; Wang, X.; Saito, J.; Tanino, Y.; Ishida, T.; Iwaki, D.; Fujita, T.; Kimura, S.; Munakata, M. Plasma UGRP1 levels associate with promoter G-112A polymorphism and the severity of asthma. Allergol. Int., 2008, 57, 57-64.
165. Tomita, T.; Kido, T.; Kurotani, R.; Iemura, S.; Sterneck, E.; Natsume, T.; Vinson, C.; Kimura, S. CAATT/enhancer-binding proteins alpha and delta interact with NKX2-1 to synergistically activate mouse secretoglobin 3A2 gene expression. J. Biol. Chem., 2008, 283, 25617-25627.
166. Bin, L.H.; Nielson, L.D.; Liu, X.; Mason, R.J.; Shu, H.B. Identification of uteroglobin-related protein 1 and macrophage scavenger receptor with collagenous structure as a lung-specific ligand-receptor pair. J. Immunol., 2003, 171, 924-930.
167. Areschoug, T.; Gordon, S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell Microbiol., 2009, 11, 1160-1169.
168. Kraal, G.; van der Laan, L.J.; Elomaa, O.; Tryggvason, K. The macrophage receptor MARCO. Microbes Infect., 2000, 2, 313-316.
169. Thakur, S.A.; Beamer, C.A.; Migliaccio, C.T.; Holian, A. Critical role of MARCO in crystalline silica-induced pulmonary inflammation. Toxicol. Sci, 2009, 108, 462-471.
170. Chu, X.; Dong, C.; Lei, R.; Sun, L.; Wang, Z.; Dong, Y.; Shen, M.; Wang, Y.; Wang, B.; Zhang, K.; Yang, L.; Li, Y.; Yuan, W.; Wang, Y.; Song, H.; Jin, L.; Xiong, M.; Huang, W. Polymorphisms in the interleukin 3 gene show strong association with susceptibility to Graves' disease in Chinese population. Genes Immun., 2009, 10, 260-266.
171. Zhu, W.; Liu, N.; Zhao, Y.; Jia, H.; Cui, B.; Ning, G. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves' disease. J. Endocrinol. Invest., 2010, 33, 751-755.
172. Jazdzewski, K.; Bednarczuk, T.; Stepnowska, M.; Liyanarachchi, S.; Suchecka-Rachon, K.; Limon, J.; Narkiewicz, K. beta-2- Adrenergic receptor gene polymorphism confers susceptibility to Graves disease. Int. J. Mol. Med., 2007, 19, 181-186.
173. Chu, X.; Dong, Y.; Shen, M.; Sun, L.L.; Dong, C.Z.; Wang, Y.; Wang, B.L.; Zhang, K.Y.; Hua, Q.; Xu, S.J.; Huang, W. Polymorphisms in the ADRB2 gene and Graves disease: a casecontrol study and a meta-analysis of available evidence. BMC Medical Genetics, 2009, 10.
174. Todd, J.A.; Walker, N.M.; Cooper, J.D.; Smyth, D.J.; Downes, K.; Plagnol, V.; Bailey, R.; Nejentsev, S.; Field, S.F.; Payne, F.; Lowe, C.E.; Szeszko, J.S.; Hafler, J.P.; Zeitels, L.; Yang, J.H.M.; Vella, A.; Nutland, S.; Stevens, H.E.; Schuilenburg, H.; Coleman, G.; Maisuria, M.; Meadows, W.; Smink, L.J.; Healy, B.; Burren, O.S.; Lam, A.A.C.; Ovington, N.R.; Allen, J.; Adlem, E.; Leung, H.T.; Wallace, C.; Howson, J.M.M.; Guja, C.; Ionescu-Tirgoviste, C.; Simmonds, M.J.; Heward, J.M.; Gough, S.C.L.; Dunger, D.B.; Wicker, L.S.; Clayton, D.G. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet., 2007, 39, 857-864.
175. van Heel, D.A.; Franke, L.; Hunt, K.A.; Gwilliam, R.; Zhernakova, A.; Inouye, M.; Wapenaar, M.C.; Barnardo, M.C.N.M.; Bethel, G.; Holmes, G.K.T.; Feighery, C.; Jewell, D.; Kelleher, D.; Kumar, P.; Travis, S.; Walters, J.R.; Sanders, D.S.; Howdle, P.; Swift, J.; Playford, R.J.; McLaren, W.M.; Mearin, M.L.; Mulder, C.J.; McManus, R.; McGinnis, R.; Cardon, L.R.; Deloukas, P.; Wijmenga, C. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet., 2007, 39, 827-829.
176. Festen, E.A.M.; Goyette, P.; Scott, R.; Annese, V.; Zhernakova, A.; Lian, J.; Lef C.; Brant, S.R.; Cho, J.H.; Silverberg, M.S.; Taylor, K.D.; de Jong, D.J.; Stokkers, P.C.; Mcgovern, D.; Palmieri, O.; Achkar, J.P.; Xavier, R.J.; Daly, M.J.; Duerr, R.H.; Wijmenga, C.; Weersma, R.K.; Rioux, J.D. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut, 2009, 58, 799-04.
177. Zhernakova, A.; Alizadeh, B.Z.; Bevova, M.; van Leeuwen, M.A.; Coenen, M.J.H.; Franke, B.; Franke, L.; Posthumus, M.D.; van Heel, D.A.; van der Steege, G.; Radstake, T.R.D.J.; Barrera, P.; Roep, B.O.; Koeleman, B.P.C.; Wijmenga, C. Novel Association in Chromosome 4q27 Region with Rheumatoid Arthritis and Confirmation of Type 1 Diabetes Point to a General Risk Locus for Autoimmune Diseases. Am. J. Hum. Genet., 2007, 81, 1284-1288.
178. Hinks, A.; Eyre, S.; Ke, X.; Barton, A.; Martin, P.; Flynn, E.; Packham, J.; Worthington, J.; Thomson, W. Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. Genes Immun., 2010, 11, 194-198.
179. Liu, Y.; Helms, C.; Liao, W.; Zaba, L.C.; Duan, S.; Gardner, J.; Wise, C.; Miner, A.; Malloy, M.J.; Pullinger, C.R.; Kane, J.P.; Saccone, S.; Worthington, J.; Bruce, I.; Kwok, P.; Menter, A.; Krueger, J.; Barton, A.; Saccone, N.L.; Bowcock, A.M. A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genet., 2008, 4, e1000041.
180. Maiti, A.K.; Kim-Howard, X.; Viswanathan, P.; Guilln, L.; Rojas- Villarraga, A.; Deshmukh, H.; Direskeneli, H.; Saruhan- Direskeneli, G.; Caas, C.; Tobân, G.J.; Sawalha, A.H.; Cheravsky, A.C.; Anaya, J.M.; Nath, S.K. Confirmation of an association between rs6822844 at the Il2GÇôIl21 region and multiple autoimmune diseases: Evidence of a general susceptibility locus. Arthritis Rheum., 2010, 62, 323-329.
181. Hollis-Moffatt, J.; Chen-Xu, M.; Topless, R.; Dalbeth, N.; Gow, P.; Harrison, A.; Highton, J.; Jones, P.; Nissen, M.; Smith, M.; van Rij, A.; Jones, G.; Stamp, L.; Merriman, T. Only one independent genetic association with rheumatoid arthritis within the KIAA1109- TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genomewide level of significance. Arthritis Res. Ther., 2010, 12, R116.
182. Gregory, S.G.; Schmidt, S.; Seth, P.; Oksenberg, J.R.; Hart, J.; Prokop, A.; Caillier, S.J.; Ban, M.; Goris, A.; Barcellos, L.F.; Lincoln, R.; McCauley, J.L.; Sawcer, S.J.; Compston, D.A.S.; Dubois, B.; Hauser, S.L.; Garcia-Blanco, M.A.; Pericak-Vance, M.A.; Haines, J.L. Interleukin 7 receptor + chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet., 2007, 39, 1083-1091.
183. Hafler, D.A.; Compston, A.; Sawcer, S.; Lander, E.S.; Daly, M.J.; De Jager, P.L.; De Bakker, P.I.W.; Gabriel, S.B.; Mirel, D.B.; Ivinson, A.J.; Pericak-Vance, M.A.; Gregory, S.G.; Rioux, J.D.; McCauley, J.L.; Haines, J.L.; Barcellos, L.F.; Cree, B.; Oksenberg, J.R.; Hauser, S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med., 2007, 357, 851-862.
184. Hoffjan, S.; Akkad, D.A. The genetics of multiple sclerosis: An update 2010. Mol. Cell. Probes, 2010, 24, 237-243.
185. Sutherland, A.; Davies, J.; Owen, C.J.; Vaikkakara, S.; Walker, C.; Cheetham, T.D.; James, R.A.; Perros, P.; Donaldson, P.T.; Cordell, H.J.; Quinton, R.; Pearce, S.H.S. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to graves' disease susceptibility. J. Clin. Endocrinol. Metab., 2007, 92, 3338-3341.
186. Penna-Martinez, M.; Ramos-Lopez, E.; Robbers, I.; Kahles, H.; Hahner, S.; Willenberg, H.; Reisch, N.; Seidl, C.; Segni, M.; Badenhoop, K. The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves' disease, Hashimoto's thyroiditis and Addison's disease. BMC Med. Genet., 2009, 10, 126.
187. Zhao, Z.F.; Cui, B.; Chen, H.Y.; Wang, S.; Li, I.; Gu, X.J.; Qi, L.; Li, X.Y.; Ning, G.; Zhao, Y.J. The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to GravesGÇÖ disease in Chinese population. Endocrine, 2007, 32, 143-147.
188. Ban, Y.; Tozaki, T.; Taniyama, M.; Nakano, Y.; Ban, Y.; Hirano, T. Genomic polymorphism in the interferon-induced helicase (IFIH1) gene does not confer susceptibility to autoimmune thyroid disease in the Japanese population. Horm. Metab. Res., 2010, 42, 70-72.
189. Smyth, D.J.; Cooper, J.D.; Bailey, R.; Field, S.; Burren, O.; Smink, L.J.; Guja, C.; Ionescu-Tirgoviste, C.; Widmer, B.; Dunger, D.B.; Savage, D.A.; Walker, N.M.; Clayton, D.G.; Todd, J.A. A genomewide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet., 2006, 38, 647-619.
190. Jermendy, A.; Szatmári, I.; Laine, A.P.; Lukács, K.; Horváth, K.H.; Körner, A.; Madácsy, L.; Veijola, R.; Simell, O.; Knip, M.; Ilonen, J.; Hermann, R.; Finnish Paediatric Diabetes Registry; HUNT1DGENES Programme. The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations. Diabetologia, 2010, 53, 98-102.
191. Martinez, A.; Santiago, J.L.; Cenit, M.C.; las Heras, V.; de la Calle, H.; Fernandez-Arquero, M.; Arroyo, R.; de la Concha, E.G.; Urcelay, E. IFIH1-GCA-KCNH7 locus: influence on multiple sclerosis risk. Eur. J. Hum. Genet., 2008, 16, 861-864.
192. Enevold, C.; Oturai, A.B.; Sorensen, P.S.; Ryder, L.P.; Koch- Henriksen, N.; Bendtzen, K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J. Neuroimmunol., 2009, 212, 125-131.
193. Martinez, A.; Varad, J.; Lamas, J.R.; Fernandez-Arquero, M.; Jover, J.A.; de la Concha, E.G.; Fernandez-Gutirrez, B.; Urcelay, E. Association of the IFIH1-GCA-KCNH7 chromosomal region with rheumatoid arthritis. Ann. Rheum. Dis., 2008, 67, 137-138.
194. Marinou, I.; Montgomery, D.; Dickson, M.; Binks, M.; Moore, D.; Bax, D.; Wilson, A. The interferon induced with helicase domain 1 A946T polymorphism is not associated with rheumatoid arthritis. Arthritis Res. Ther., 2007, 9, R40.
195. Li, Y.H.; Liao, W.; Cargill, M.; Chang, M.; Matsunami, N.; Feng, B.J.; Poon, A.; Callis-Duffin, K.P.; Catanese, J.J.; Bowcock, A.M.; Leppert, M.F.; Kwok, P.Y.; Krueger, G.G.; Begovich, A.B. Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis. J. Invest. Dermatol., 2010, 130, 2768-2772.
196. Gateva, V.; Sandling, J.K.; Hom, G.; Taylor, K.E.; Chung, S.A.; Sun, X.; Ortmann, W.; Kosoy, R.; Ferreira, R.C.; Nordmark, G.; Gunnarsson, I.; Svenungsson, E.; Padyukov, L.; Sturfelt, G.; Jonsen, A.; Bengtsson, A.A.; Rantapaa-Dahlqvist, S.; Baechler, E.C.; Brown, E.E.; Alarcon, G.S.; Edberg, J.C.; Ramsey-Goldman, R.; McGwin, G.; Reveille, J.D.; Vila, L.M.; Kimberly, R.P.; Manzi, S.; Petri, M.A.; Lee, A.; Gregersen, P.K.; Seldin, M.F.; Ronnblom, L.; Criswell, L.A.; Syvanen, A.C.; Behrens, T.W.; Graham, R.R. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet., 2009, 41, 1228-1233.
197. Nejentsev, S.; Walker, N.; Riches, D.; Egholm, M.; Todd, J.A. Rare Variants of IFIH1, a Gene Implicated in Antiviral Responses, Protect Against Type 1 Diabetes. Science, 2009 1167728.
198. Chistiakov, D.A. Interferon Induced with Helicase C Domain 1 (IFIH1) and Virus-Induced Autoimmunity: A Review. Viral Immunol., 2010, 23, 3-15.
199. Shigemoto, T.; Kageyama, M.; Hirai, R.; Zheng, J.; Yoneyama, M.; Fujita, T. Identification of Loss of Function Mutations in Human Genes Encoding RIG-I and MDA5. J. Biol. Chem., 2009, 284, 13348-13354.
200. Liu, S.; Wang, H.; Jin, Y.; Podolsky, R.; Reddy, M.P.L.; Pedersen, J.; Bode, B.; Reed, J.; Steed, D.; Anderson, S.; Yang, P.; Muir, A.; Steed, L.; Hopkins, D.; Huang, Y.; Purohit, S.; Wang, C.Y.; Steck, A.K.; Montemari, A.; Eisenbarth, G.; Rewers, M.; She, J.X. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum. Mol. Genet., 2009, 18, 358-365.
201. Downes, K.; Pekalski, M.; Angus, K.L.; Hardy, M.; Nutland, S.; Smyth, D.J.; Walker, N.M.; Wallace, C.; Todd, J.A. Reduced expression of IFIH1 is protective for type 1 diabetes. PLoS ONE, 2010, 5, e12646.
202. Zouk, H.; Marchand, L.; Polychronakos, C. Study of transcriptional effects in Cis at the IFIH1 locus. PLoS ONE, 2010, 5, e11564.
203. Ma, C.; Staudt, L.M. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood, 1996, 87, 734-745.
204. Barton, A.; Eyre, S.; Ke, X.; Hinks, A.; Bowes, J.; Flynn, E.; Martin, P.; YEAR Consortium; BIRAC Consortium; Wilson, A.G.; Morgan, A.W.; Emery, P.; Steer, S.; Hocking, L.J.; Reid, D.M.; Harrison, P.; Wordsworth, P.; Thomson, W.; Worthington, J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum. Mol. Genet., 2009, 18, 2518-2522.
205. Bottino, C.; Castriconi, R.; Pende, D.; Rivera, P.; Nanni, M.; Carnemolla, B.; Cantoni, C.; Grassi, J.; Marcenaro, S.; Reymond, N.; Vitale, M.; Moretta, L.; Lopez, M.; Moretta, A. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med., 2003, 198, 557-567.
206. Shibuya, A.; Campbell, D.; Hannum, C.; Yssel, H.; Franz-Bacon, K.; McClanahan, T.; Kitamura, T.; Nicholl, J.; Sutherland, G.R.; Lanier, L.L.; Phillips, J.H. DNAM-1, A novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity, 1996, 4, 573-581.
207. Xu, Z.; Jin, B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell. Mol. Immunol., 2010, 7, 11-19.
208. Hafler, J.P.; Maier, L.M.; Cooper, J.D.; Plagnol, V.; Hinks, A.; Simmonds, M.J.; Stevens, H.E.; Walker, N.M.; Healy, B.; Howson, J.M.M.; Maisuria, M.; Duley, S.; Coleman, G.; Gough, S.C.L.; Worthington, J.; Kuchroo, V.K.; Wicker, L.S.; Todd, J.A. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun., 2008.
209. Lofgren, S.E.; Delgado-Vega, A.M.; Gallant, C.J.; Saínchez, E.; Frostegard, J.; Truedsson, L.; Ramon Garrido, E.; Sabio, J.M.; Gonzaílez-Escribano, M.F.; Pons-Estel, B.A.; D'Alfonso, S.; Witte, T.; Lauwerys, B.R.; Endreffy, E.; Kovícs, L,; Vasconcelos, C.; Martins da Silva, B.; Marten, J.; Alarc-n-Riquelme, M.E.; Kozyrev, S.V. A 3GÇ--untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum., 2010, 62, 3404-3414.
210. Wieczorek, S.; Hoffjan, S.; Chan, A.; Rey, L.; Harper, L.; Fricke, H.; Holle, J.U.; Gross, W.L.; Epplen, J.T.; Lamprecht, P. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun., 2009, 10, 591-595.
211. Dieude, P.; Guedj, M.; Truchetet, M.E.; Wipff, J.; Revillod, L.; Riemekasten, G.; Matucci-Cerinic, M.; Melchers, I.; Hachulla, E.; Airo, P.; Diot, E.; Hunzelmann, N.; Mouthon, L.; Cabane, J.; Cracowski, J.L.; Riccieri, V.; Distler, J.; Amoura, Z.; Valentini, G.; Camaraschi, P.; Tarner, I.; Frances, C.; Carpentier, P.; Brembilla, N.C.; Meyer, O.; Kahan, A.; Chizzolini, C.; Boileau, C.; Allanore, Y. Association of the CD226 Ser307 variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum., 2011, 63, 1097-1105.
212. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447, 661-678.
213. Franke, A.; Balschun, T.; Karlsen, T.H.; Hedderich, J.; May, S.; Lu, T.; Schuldt, D.; Nikolaus, S.; Rosenstiel, P.; Krawczak, M.; Schreiber, S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet., 2008, 40, 713-715.
214. Thompson, S.D.; Sudman, M.; Ramos, P.S.; Marion, M.C.; Ryan, M.; Tsoras, M.; Weiler, T.; Wagner, M.; Keddache, M.; Haas, J.P.; Mueller, C.; Prahalad, S.; Bohnsack, J.; Wise, C.A.; Punaro, M.; Zhang, D.; Ros, C.D.; Comeau, M.E.; Divers, J.; Glass, D.N.; Langefeld, C.D. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum., 2010, 62, 3265-3276.
215. Smyth, D.J.; Plagnol, V.; Walker, N.M.; Cooper, J.D.; Downes, K.; Yang, J.H.M.; Howson, J.M.M.; Stevens, H.; McManus, R.; Wijmenga, C.; Heap, G.A.; Dubois, P.C.; Clayton, D.G.; Hunt, K.A.; van Heel, D.A.; Todd, J.A. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med., 2008, 359, 2767-2777.
216. Doody, K.M.; Bourdeau, A.; Tremblay, M.L. T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol. Rev., 2009, 228, 325-341.
217. Ban, Y.; Taniyama, M.; Ban, Y. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J. Clin. Endocrinol. Metab., 2000, 85, 4639-4643.
218. Ban, Y.; Ban, Y.; Taniyama, M.; Katagiri, T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid, 2000, 10, 475-480.
219. Huber, A.K.; Jacobson, E.M.; Jazdzewski, K.; Concepcion, E.S.; Tomer, Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J. Clin. Endocrinol. Metab., 2008, 93, 1077-1081.
220. Kisiel, B.; Bednarczuk, T.; Kostrzewa, G.; Kosinska, J.; kiewicz, P.; Plazinska, M.T.; Bar-Andziak, E.; Krolicki, L.; Krajewski, P.; Ploski, R. Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease. Clin. Endocrinol. (Oxf), 2008, 68, 429-434.
221. Kisiel, B.M.; Kosinska, J.; Wierzbowska, M.; Rutkowska-Sak, L.; Musiej-Nowakowska, E.; Wudarski, M.; Olesinska, M.; Krajewski, P.; Lacki, J.; Rell-Bakalarska, M.; Jagodzinski, P.P.; Tlustochowicz, W.; Ploski, R. Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus, 2011, 20, 85-89.
222. Putnik, M.; Zhao, C.; Gustafsson, J.A.; Dahlman-Wright, K. Effects of two common polymorphisms in the 3 ' untranslated regions of estrogen receptor beta on mRNA stability and translatability. BMC Genetics, 2009, 10.
223. Kurylowicz, A.; Hiromatsu, Y.; Jurecka-Lubieniecka, B.; Kula, D.; Kowalska, M.; Ichimura, M.; Koga, H.; Kaku, H.; Bar-Andziak, E.; Nauman, J.; Jarzab, B.; Ploski, R.; Bednarczuk, T. Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. Genes Immun., 2007, 8, 532-538.
224. Karban, A.S.; Okazaki, T.; Panhuysen, C.I.M.; Gallegos, T.; Potter, J.J.; Bailey-Wilson, J.E.; Silverberg, M.S.; Duerr, R.H.; Cho, J.H.; Gregersen, P.K.; Wu, Y.; Achkar, J.P.; Dassopoulos, T.; Mezey, E.; Bayless, T.M.; Nouvet, F.J.; Brant, S.R. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet., 2004, 13, 35-45.
225. Zou, Y.F.; Wang, F.; Feng, X.L.; Tao, J.H.; Zhu, J.M.; Pan, F.M.; Su, H. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens, 2011, 77, 9-17.
226. Baldwin, A.S. Series Introduction: The transcription factor NFkappaB and human disease. J. Clin. Invest., 2001, 107, 3-6.
227. Brown, C.J. Skewed X-chromosome inactivation: cause or consequence? J. Natl. Cancer Inst., 1999, 91, 304-305.
228. Kristiansen, M.; Knudsen, G.P.S.; Bathum, L.; Naumova, A.K.; Sorensen, T.I.A.; Brix, T.H.; Svendsen, A.J.; Christensen, K.; Kyvik, K.O.; Ørstavik, K.H. Twin study of genetic and aging effects on X chromosome inactivation. Eur. J. Hum. Genet., 2005, 13, 599-606.
229. Christensen, K.; Kristiansen, M.; Hagen-Larsen, H.; Skylthe, A.; Bathum, L.; Jeune, B.; Andersen-Ranberg, K.; Vaupel, J.W.; Ørstavik, K.H. X-linked genetic factors regulate hematopoietic stem-cell kinetics in females. Blood, 2000, 95, 2449-2451.
230. Vickers, M.A.; McLeod, E.; Spector, T.D.; Wilson, I.J. Assessment of mechanism of acquired skewed X inactivation by analysis of twins. Blood, 2001, 97, 1274-1281.
231. Naumova, A.K.; Olien, L.; Bird, L.M.; Smith, M.; Verner, A.E.; Leppert, M.; Morgan, K.; Sapienza, C. Genetic mapping of Xlinked loci involved in skewing of X chromosome inactivation in the human. Eur. J. Hum. Genet., 1998, 6, 552-562.
232. Sharp, A.; Robinson, D.; Jacobs, P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum.Genet., 2000, 107, 343-349.
233. Brix, T.H.; Knudsen, G.P.; Kristiansen, M.; Kyvik, K.O.; Orstavik, K.H.; Hegedus, L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J. Clin. Endocrinol. Metab., 2005, 90, 5949-5953.
234. Ozcelik, T.; Uz, E.; Akyerli, C.B.; Bagislar, S.; Mustafa, C.A.; Gursoy, A.; Akarsu, N.; Toruner, G.; Kamel, N.; Gullu, S. Evidence from autoimmune thyroiditis of skewed X-chromosome inactivation in female predisposition to autoimmunity. Eur. J. Hum. Genet., 2006, 14, 791-797.
235. Yin, X.; Latif, R.; Tomer, Y.; Davies, T.F. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann. N. Y. Acad. Sci., 2007, 1110, 193-200.
236. Chabchoub, G.; Uz, E.; Maalej, A.; Mustafa, C.A.; Rebai, A.; Mnif, M.; Bahloul, Z.; Farid, N.R.; Ozcelik, T.; Ayadi, H. Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases. Arthritis Res. Ther., 2009, 11, R106.
237. Kast, R.E. Hypothesis - Predominance of Autoimmune and Rheumatic Diseases in Females. J. Rheum., 1977, 4, 288-292.
238. Stewart, J.J. The female X-inactivation mosaic in systemic lupus erythematosus. Immunol. Today, 1998, 19, 352-357.
239. Ozcelik, T. X chromosome inactivation and female predisposition to autoimmunity. Clin. Rev. Allergy Immunol., 2008, 34, 348-351.
240. Chitnis, S.; Monteiro, J.; Glass, D.; Apatoff, B.; Salmon, J.; Concannon, P.; Gregersen, P.K. The role of X-chromosome inactivation in female predisposition to autoimmunity. Arthritis Res., 2000, 2, 399-406.
241. Knudsen, G.P.S.; Harbo, H.F.; Smestad, C.; Celius, E.G.; Akesson, E.; Oturai, A.; Ryder, L.P.; Spurkland, A.; Orstavik, K.H. X chromosome inactivation in females with multiple sclerosis. Eur. J. Neurol., 2007, 14, 1392-1396.
242. Miozzo, M.; Selmi, C.; Gentilin, B.; Grati, F.R.; Sirchia, S.; Oertelt, S.; Zuin, M.; Gershwin, M.E.; Podda, M.; Invernizzi, P. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology, 2007, 46, 456-462.
243. Smith-Bouvier, D.L.; Divekar, A.A.; Sasidhar, M.; Du, S.; Tiwari- Woodruff, S.K.; King, J.K.; Arnold, A.P.; Singh, R.R.; Voskuhl, R.R. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med., 2008, 205, 1099-1108.
244. Brix, T.H.; Hansen, P.S.; Kyvik, K.O.; Hegedus, L. Preliminary evidence of a noncausal association between the X-chromosome inactivation pattern and thyroid autoimmunity: a twin study. Eur. J. Hum. Genet., 2009, 18, 254-257.
245. Elsheikh, M.; Wass, J.A.; Conway, G.S. Autoimmune thyroid syndrome in women with Turner's syndrome--the association with karyotype. Clin. Endocrinol. (Oxf), 2001, 55, 223-226.
246. Invernizzi, P.; Miozzo, M.; Selmi, C.; Persani, L.; Battezzati, P.M.; Zuin, M.; Lucchi, S.; Meroni, P.L.; Marasini, B.; Zeni, S.; Watnik, M.; Grati, F.R.; Simoni, G.; Gershwin, M.E.; Podda, M. X chromosome monosomy: a common mechanism for autoimmune diseases. J. Immunol., 2005, 175, 575-578.
247. Barbesino, G.; Tomer, Y.; Concepcion, E.S.; Davies, T.F.; Greenberg, D.A. Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome. International consortium for the genetics of autoimmune thyroid disease. J. Clin. Endocrinol. Metab., 1998, 83, 3290-3295.
248. Imrie, H.; Vaidya, B.; Perros, P.; Kelly, W.F.; Toft, A.D.; Young, E.T.; Kendall-Taylor, P.; Pearce, S.H. Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population. J. Clin. Endocrinol. Metab., 2001, 86, 626-630.
249. Bianchi, D.W.; Zickwolf, G.K.; Weil, G.J.; Sylvester, S.; DeMaria, M.A. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. PNAS, 1996, 93, 705-708.
250. Kennedy, R.L.; Malabu, U.H.; Jarrod, G.; Nigam, P.; Kannan, K.; Rane, A. Thyroid function and pregnancy: Before, during and beyond. J. Obstet. Gynaecol., 2010, 30, 774-783.
251. Ando, T.; Davies, T.F. Postpartum Autoimmune Thyroid Disease: The Potential Role of Fetal Microchimerism. J. Clin. Endocrinol. Metab., 2003, 88, 2965-2971.
252. Srivatsa, B.; Srivatsa, S.; Johnson, K.L.; Samura, O.; Lee, S.L.; Bianchi, D.W. Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study. Lancet, 2001, 358, 2034-2038.
253. Klintschar, M.; Schwaiger, P.; Mannweiler, S.; Regauer, S.; Kleiber, M. Evidence of Fetal Microchimerism in Hashimoto's Thyroiditis. J. Clin. Endocrinol. Metab., 2001, 86, 2494-2498.
254. Klintschar, M.; Immel, U.D.; Kehlen, A.; Schwaiger, P.; Mustafa, T.; Mannweiler, S.; Regauer, S.; Kleiber, M.; Hoang-Vu, C. Fetal microchimerism in Hashimoto's thyroiditis: a quantitative approach. Eur. J. Endocrinol., 2006, 154, 237-241.
255. Ando, T.; Imaizumi, M.; Graves, P.N.; Unger, P.; Davies, T.F. Intrathyroidal Fetal Microchimerism in Graves Disease. J. Clin. Endocrinol. Metab., 2002, 87, 3315-3320.
256. Renne, C.; Ramos Lopez, E.; Steimle-Grauer, S.A.; Ziolkowski, P.; Pani, M.A.; Luther, C.; Holzer, K.; Encke, A.; Wahl, R.A.; Bechstein, W.O.; Usadel, K.H.; Hansmann, M.L.; Badenhoop, K. Thyroid Fetal Male Microchimerisms in Mothers with Thyroid Disorders: Presence of Y-Chromosomal Immunofluorescence in Thyroid-Infiltrating Lymphocytes Is More Prevalent in HashimotoGÇÖs Thyroiditis and GravesGÇÖ Disease Than in Follicular Adenomas. J. Clin. Endocrinol. Metab., 2004, 89, 5810-5814.
257. Brix, T.H.; Hansen, P.S.; Kyvik, K.O.; Hegedus, L. Aggregation of thyroid autoantibodies in twins from opposite-sex pairs suggests that microchimerism may play a role in the early stages of thyroid autoimmunity. J. Clin. Endocrinol. Metab., 2009, 94, 4439-4443.
258. Imaizumi, M.; Pritsker, A.; Unger, P.; Davies, T.F. Intrathyroidal Fetal Microchimerism in Pregnancy and Postpartum. Endocrinology, 2002, 143, 247-253.
259. Ando, T.; Davies, T.F. Self-recognition and the role of fetal microchimerism. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 197-211.
260. Khosrotehrani, K.; Johnson, K.L.; Cha, D.H.; Salomon, R.N.; Bianchi, D.W. Transfer of fetal cells with multilineage potential to maternal tissue. JAMA, 2004, 292, 75-80.
261. Wang, Y.; Iwatani, H.; Ito, T.; Horimoto, N.; Yamato, M.; Matsui, I.; Imai, E.; Hori, M. Fetal cells in mother rats contribute to the remodeling of liver and kidney after injury. Biochem. Biophys. Res. Commun., 2004, 325, 961-967.
262. Khosrotehrani, K.; Reyes, R.R.; Johnson, K.L.; Freeman, R.B.; Salomon, R.N.; Peter, I.; Stroh, H.; Guegan, S.; Bianchi, D.W. Fetal cells participate over time in the response to specific types of murine maternal hepatic injury. Hum. Reprod., 2007, 22, 654-661.
263. Bou-Gharios, G.; Amin, F.; Hill, P.; Nakamura, H.; Maxwell, P.; Fisk, N.M. Microchimeric fetal cells are recruited to maternal kidney following injury and activate collagen type i transcription. Cells Tissues Organs, 2011, 193, 379-392.
264. O'Donoghue, K.; Sultan, H.A.; Ai-Allaf, F.A.; Anderson, J.R.; Wyatt-Ashmead, J.; Fisk, N.M. Microchimeric fetal cells cluster at sites of tissue injury in lung decades after pregnancy. Reprod. Biomed. Online, 2008, 16, 382-390.
265. Friedrich, N.; Schwarz, S.; Thonack, J.; John, U.; Wallaschofski, H.; Volzke, H. Association between parity and autoimmune thyroiditis in a general female population. Autoimmunity, 2008, 41, 174-180.
266. Phillips, D.I.; Lazarus, J.H.; Butland, B.K. The influence of pregnancy and reproductive span on the occurrence of autoimmune thyroiditis. Clin. Endocrinol. (Oxf), 1990, 32, 301-306.
267. Walsh, J.P.; Bremner, A.P.; Bulsara, M.K.; OGÇÖLeary, P.; Leedman, P.J.; Feddema, P.; Michelangeli, V. Parity and the risk of autoimmune thyroid disease: a community-based study. J. Clin. Endocrinol. Metab., 2005, 90, 5309-5312.
268. Pedersen, I.B.; Laurberg, P.; Knudsen, N.; Jorgensen, T.; Perrild, H.; Ovesen, L.; Rasmussen, L.B. Lack of association between thyroid autoantibodies and parity in a population study argues against microchimerism as a trigger of thyroid autoimmunity. Eur. J. Endocrinol., 2006, 154, 39-45.
269. Sgarbi, J.A.; Kasamatsu, T.S.; Matsumura, L.K.; Maciel, R.M.B. Parity is not related to autoimmune thyroid disease in a populationbased study of japanese-brazilians. Thyroid, 2010, 20, 1151-1156.
270. Fugazzola, L.; Cirello, V.; Beck-Peccoz, P. Fetal microchimerism as an explanation of disease. Nat. Rev. Endocrinol., 2011, 7, 89-97.
271. Brix, T.H.; Hegedus, L. Twins as a tool for evaluating the influence of genetic susceptibility in thyroid autoimmunity. Ann. Endocrinol. (Paris), 2011, 72, 103-107.
272. Bednarczuk, T.; Gopinath, B.; Ploski, R.; Wall, J.R. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clin. Endocrinol. (Oxf), 2007, 67, 3-19.
273. Kim, K.W.; Park, Y.J.; Kim, T.Y.; Park, d.J.; Park, K.S.; Cho, B.Y. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. Thyroid, 2007, 17, 1229-1234.
274. Badenhoop, K.; Donner, H.; Braun, J.; Siegmund, T.; Rau, H.; Usadel, K.H. Genetic markers in diagnosis and prediction of relapse in Graves' disease. Exp. Clin. Endocrinol. Diabetes, 1996, 104 Suppl 4, 98-100.
275. Bednarczuk, T.; Hiromatsu, Y.; Fukutani, T.; Jazdzewski, K.; Miskiewicz, P.; Osikowska, M.; Nauman, J. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur. J. Endocrinol., 2003, 148, 13-18.
276. Siegmund, T.; Usadel, K.H.; Donner, H.; Braun, J.; Walfish, P.G.; Badenhoop, K. Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease. Thyroid, 1998, 8, 1013-1017.
277. Kamizono, S.; Hiromatsu, Y.; Seki, N.; Bednarczuk, T.; Matsumoto, H.; Kimura, A.; Itoh, K. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin. Endocrinol. (Oxf), 2000, 52, 759-764.
278. Bednarczuk, T.; Hiromatsu, Y.; Seki, N.; Ploski, R.; Fukutani, T.; Kurylowicz, A.; Jazdzewski, K.; Chojnowski, K.; Itoh, K.; Nauman, J. Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum. Immunol., 2004, 65, 632-639.
279. Khalilzadeh, O.; Anvari, M.; Esteghamati, A.; Mahmoudi, M.; Tahvildari, M.; Rashidi, A.; Khosravi, F.; Amirzargar, A. Graves' ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin. Experiment. Ophthalmol., 2009, 37, 614-619.
280. Gu, X.J.; Cui, B.; Zhao, Z.F.; Chen, H.Y.; Li, X.Y.; Wang, S.; Ning, G.; Zhao, Y.J. Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease. Clin. Immunol., 2008, 127, 298-302.
281. Vaidya, B.; Oakes, E.J.; Imrie, H.; Dickinson, A.J.; Perros, P.; Kendall-Taylor, P.; Pearce, S.H. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin. Endocrinol. (Oxf), 2003, 58, 732-735.
282. Han, S.Z.; Zhang, S.H.; Li, R.; Zhang, W.Y.; Li, Y. The common - 318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int. J. Immunogenet., 2006, 33, 281-287.
283. Kretowski, A.; Wawrusiewicz, N.; Mironczuk, K.; Mysliwiec, J.; Kretowska, M.; Kinalska, I. Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. J. Clin. Endocrinol. Metab., 2003, 88, 4945-4949.
284. Syed, A.A.; Simmonds, M.J.; Brand, O.J.; Franklyn, J.A.; Gough, S.C.; Heward, J.M. Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy. Clin. Endocrinol. (Oxf), 2007, 67, 663-667.
285. Liao, W.L.; Chen, R.H.; Lin, H.J.; Liu, Y.H.; Chen, W.C.; Tsai, Y.; Wan, L.; Tsai, F.J. Toll-like receptor gene polymorphisms are associated with susceptibility to Graves' ophthalmopathy in Taiwan males. BMC Med. Genet., 2010, 11, 154.
286. Liao, W.L.; Chen, R.H.; Lin, H.J.; Liu, Y.H.; Chen, W.C.; Tsai, Y.; Wan, L.; Tsai, F.J. The association between polymorphisms of B7 molecules (CD80 and CD86) and Graves' ophthalmopathy in a Taiwanese population. Ophthalmology, 2011, 118, 553-557.
287. Lavard, L.; Madsen, H.O.; Perrild, H.; Jacobsen, B.B.; Svejgaard, A. HLA class II associations in juvenile Graves' disease: indication of a strong protective role of the DRB1 0701,DQA1 0201 haplotype. Tissue Antigens, 1997, 50, 639-641.
288. Kinjo, Y.; Takasu, N.; Komiya, I.; Tomoyose, T.; Takara, M.; Kouki, T.; Shimajiri, Y.; Yabiku, K.; Yoshimura, H. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J. Clin. Endocrinol. Metab., 2002, 87, 2593-2596.
289. Kimura, H.; Kato, Y.; Shimizu, S.; Takano, K.; Sato, K. Association of polymorphism at position 49 in exon 1 of the cytotoxic T-lymphocyte-associated factor 4 gene with Graves' disease refractory to medical treatment, but not with amiodaroneassociated thyroid dysfunction. Thyroid, 2009, 19, 975-981.
290. Wang, P.W.; Chen, I.Y.; Liu, R.T.; Hsieh, C.J.; Hsi, E.; Juo, S.H. Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: a follow-up study. J. Clin. Endocrinol. Metab., 2007, 92, 2513-2518.
291. Bruck, P.; Bartsch, W.; Sadet, D.; Penna-Martinez, M.; Kurylowicz, A.; Bednarczuk, T.; Robbers, I.; Paunkovic, J.; Bohme, A.; Badenhoop, K.; Ramos-Lopez, E. A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves' disease. Thyroid, 2010, 20, 343-345.
292. Zaletel, K.; Krhin, B.; Gaberscek, S.; Pirnat, E.; Hojker, S. The influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Thyroid, 2002, 12, 373-376.
293. Inoue, N.; Watanabe, M.; Nanba, T.; Wada, M.; Akamizu, T.; Iwatani, Y. Involvement of functional polymorphisms in the TNFA gene in the pathogenesis of autoimmune thyroid diseases and production of anti-thyrotropin receptor antibody. Clin. Exp. Immunol., 2009, 156, 199-204.